Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.

Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, McFarlane P, Pandeya S, Tam P, Bichet DG.

Can J Kidney Health Dis. 2017 Mar 1;4:2054358117695784. doi: 10.1177/2054358117695784. eCollection 2017.

2.

Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes.

Rajoriya N, Tripathi D, Leithead JA, Gunson BK, Lord S, Ferguson JW, Hirschfield GM.

World J Gastroenterol. 2016 Dec 7;22(45):9966-9973. doi: 10.3748/wjg.v22.i45.9966.

3.

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.

Lantinga MA, D'Agnolo HM, Casteleijn NF, de Fijter JW, Meijer E, Messchendorp AL, Peters DJ, Salih M, Spithoven EM, Soonawala D, Visser FW, Wetzels JF, Zietse R, Drenth JP, Gansevoort RT; DIPAK Consortium..

Drug Saf. 2017 Feb;40(2):153-167. doi: 10.1007/s40264-016-0486-x.

4.

Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes.

Wills ES, Cnossen WR, Veltman JA, Woestenenk R, Steehouwer M, Salomon J, Te Morsche RH, Huch M, Hehir-Kwa JY, Banning MJ, Pfundt R, Roepman R, Hoischen A, Drenth JP.

Eur J Hum Genet. 2016 Dec;24(12):1707-1714. doi: 10.1038/ejhg.2016.97. Epub 2016 Aug 24.

PMID:
27552964
5.

Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images.

Kline TL, Edwards ME, Korfiatis P, Akkus Z, Torres VE, Erickson BJ.

AJR Am J Roentgenol. 2016 Sep;207(3):605-13. doi: 10.2214/AJR.15.15875. Epub 2016 Jun 24.

6.

Heterotrimeric G protein signaling in polycystic kidney disease.

Hama T, Park F.

Physiol Genomics. 2016 Jul 1;48(7):429-45. doi: 10.1152/physiolgenomics.00027.2016. Epub 2016 May 13. Review.

PMID:
27199453
7.

Polycystic Liver Disease: The Benefits of Targeting cAMP.

Larusso NF, Masyuk TV, Hogan MC.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1031-4. doi: 10.1016/j.cgh.2016.03.008. Epub 2016 Mar 10. No abstract available.

PMID:
26972981
8.

Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.

Neijenhuis MK, Gevers TJ, Hogan MC, Kamath PS, Wijnands TF, van den Ouweland RC, Edwards ME, Sloan JA, Kievit W, Drenth JP.

Hepatology. 2016 Jul;64(1):151-60. doi: 10.1002/hep.28545. Epub 2016 Apr 15.

PMID:
26970415
9.

Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.

Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, Torres VE, El-Zoghby ZM.

Nephrol Dial Transplant. 2016 Jun;31(6):952-60. doi: 10.1093/ndt/gfw008. Epub 2016 Feb 29.

PMID:
26932689
10.

Medical therapy for polycystic liver disease.

Khan S, Dennison A, Garcea G.

Ann R Coll Surg Engl. 2016 Jan;98(1):18-23. doi: 10.1308/rcsann.2016.0023. Review.

11.

Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.

Kim H, Park HC, Ryu H, Kim K, Kim HS, Oh KH, Yu SJ, Chung JW, Cho JY, Kim SH, Cheong HI, Lee K, Park JH, Pei Y, Hwang YH, Ahn C.

PLoS One. 2015 Dec 7;10(12):e0144526. doi: 10.1371/journal.pone.0144526. eCollection 2015.

12.

Epidemiology of CKD Regression in Patients under Nephrology Care.

Borrelli S, Leonardis D, Minutolo R, Chiodini P, De Nicola L, Esposito C, Mallamaci F, Zoccali C, Conte G.

PLoS One. 2015 Oct 13;10(10):e0140138. doi: 10.1371/journal.pone.0140138. eCollection 2015.

13.

Current management of autosomal dominant polycystic kidney disease.

Akoh JA.

World J Nephrol. 2015 Sep 6;4(4):468-79. doi: 10.5527/wjn.v4.i4.468. Review.

14.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE.

Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.

15.

TGR5 in the Cholangiociliopathies.

Masyuk TV, Masyuk AI, LaRusso NF.

Dig Dis. 2015;33(3):420-5. doi: 10.1159/000371696. Epub 2015 May 27.

16.

Volume regression of native polycystic kidneys after renal transplantation.

Jung Y, Irazabal MV, Chebib FT, Harris PC, Dean PG, Prieto M, Cosio FG, El-Zoghby ZM, Torres VE.

Nephrol Dial Transplant. 2016 Jan;31(1):73-9. doi: 10.1093/ndt/gfv227. Epub 2015 Jun 4.

17.

Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM.

J Hepatol. 2015 Oct;63(4):952-61. doi: 10.1016/j.jhep.2015.05.023. Epub 2015 Jun 1.

18.

Night blindness in a haemodialysed ADPKD patient receiving octreotide.

Ho TA, Decleire PY, Lafontaine JJ, Pirson Y.

Clin Kidney J. 2012 Oct;5(5):474-5. doi: 10.1093/ckj/sfs121. No abstract available.

19.

The Cholangiopathies.

Lazaridis KN, LaRusso NF.

Mayo Clin Proc. 2015 Jun;90(6):791-800. doi: 10.1016/j.mayocp.2015.03.017. Epub 2015 May 6. Review.

20.

Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Saigusa T, Bell PD.

Physiology (Bethesda). 2015 May;30(3):195-207. doi: 10.1152/physiol.00032.2014. Review.

Supplemental Content

Support Center